In addition to its clinical advantages, QCT offers a significant cost-effectiveness advantage, particularly in comparison to DXA. QCT PRO gives you a realistic opportunity to profit from your investment, quite possibly significantly. With a system that utilizes existing equipment and staff, a price between $14,500 and $27,000 with virtually no additional or recurring costs, and with reimbursements in the $140 range, it takes only a small number of patients to become profitable.

In stark contrast, DXA requires a significant capital investment, requires additional existing floor space, often room preparation, staffing, service contracts and other recurring cost, DXA systems require significantly more patient to cover basic operating costs. If you closely examine the numbers we think you will find that QCT PRO is about 4 times more cost-effective than DXA. In other words, the break even patient volume is about one-fourth, or the profit potential is about 4 times greater.

Here are 4 links that can help you to analyze the economics of QCT for your site:

BMD Financial Analyzer Software

A free program that lets you input patient demographics and operating costs and calculates profit and loss. Can compare two systems. Sample QCT vs. DXA Cost Analysis

A sample report from BMD FA software that compares QCT to DXA.

HCFA Guidelines

The latest guidelines from HCFA Reimbursement Codes

WILL YOUR BMD SYSTEM BE PROFITABLE?

Financial Analyzer is software that you can use to estimate your annual profits based on your patient referral base, costs to acquire and maintain a bone densitometry system, and per-exam expenditures and payments. This information is input in a simple, yet flexible, manner that can support a broad range of system financing options and cost-accounting schemes.

Financial Analyzer can assist you in cost and profit comparisons of various bone densitometry systems. For example, the cost of installing a QCT bone densitometry system for use with an existing CT installation will typically be dominated by the capital expenditure for the QCT package. In contrast, a DXA system may involve significant expenses for system siting and personnel to operate the DXA scanner. Differences in operational costs due to, for example, differences in the time to perform a bone density study using 2 different QCT packages can also be modeled.

Financial Analyzer assists you in estimating the patient referral rate you need to achieve your financial goals. Patient referral rate is, perhaps, the least well known of the many input parameters you may define. Estimates by the NOF indicate that only about 10% of women at risk for osteoporosis in a typical community are currently being screened for low bone density–the single most important risk factor for osteoporosis. Increasing awareness in the need for osteoporosis screening and the International Society of Clinical Densitometry recommendation that patients screened by hand, arm or heel methods and found to have low bone density be referred for a central BMD measurement (QCT or DXA) suggest that the referring population for QCT will increase substantially in coming years. Evaluating your patient referral base may be one of the best ways to estimate the long-term potential return on your investment. We hope that you find Financial Analyzer useful and that it provides you with yet another reason for purchasing a QCT bone densitometry system from Mindways.

FEATURES AT A GLANCE

• Helps you estimate your patient referral base.
• Helps you estimate costs and returns.
• Helps you compare different systems, e.g., QCT vs. DXA or QCT vs. QCT.
• Estimates breakeven patient referral rates.
• Estimates annual revenue and profit.
• Prints comprehensive, site-personalized reports.
• Includes predefined values for common technologies.
• Windows® 95/98/NT compatible.